You have been successfully logged out.
The only pan-genotypic, pan-fibrotic, single-tablet regimen for the treatment of patients with chronic hepatitis C infection1
EPCLUSA® (sofosbuvir/velpatasvir) is indicated for the treatment of chronic hepatitis C virus (HCV) infection, genotypes 1 to 6, in adults and paediatric patients ≥12 years of age and weighing ≥30 kg.1
Access information, clinical resources and support for prescribing EPCLUSA®, and discover the latest EPCLUSA® news.
Need to get in touch with the team? We are all ears.
Reference: 1. EPCLUSA Approved Product Information 2022.
Please review the Epclusa Approved Product Information before prescribing. For Full Product Information, please click here.
EPCLUSA® PBS Information: EPCLUSA is PBS listed for the treatment of chronic genotype 1–6 hepatitis C infection. Dual
General Schedule and S100 [HSD] listing. Authority required. Refer to PBS Schedule for full authority information.